Urinary Iron Excretion in Patients with Prosthetic Heart Valves

John R. Walsh, Michael T.H. Brodeur, Leonard W. Ritzmann, Donald W. Sutherland, Albert Starr

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Intravascular destruction of erythrocytes sufficient to produce hemolytic anemia occurs with incompetent prosthetic heart valves. Renal hemosiderosis results from chronic intravascular hemolysis. Increased urinary iron loss eventually produces an iron-deficiency state even in the presence of renal hemosiderosis. Deferoxamine mesylate, an iron-chelating agent, increases the urinary iron excretion in this combination of circumstances, suggesting that it removes iron from the kidney. A compensated hemolytic state has occurred in some of these patients after iron therapy, and reoperation was thereby avoided. Elevated serum lactic dehydrogenase values indicate hemolysis and remain unchanged with iron therapy. Iron therapy had no influence on erythrocyte survival.

Original languageEnglish (US)
Pages (from-to)505-510
Number of pages6
JournalJAMA: The Journal of the American Medical Association
Volume198
Issue number5
DOIs
StatePublished - Oct 31 1966

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Urinary Iron Excretion in Patients with Prosthetic Heart Valves'. Together they form a unique fingerprint.

  • Cite this

    Walsh, J. R., Brodeur, M. T. H., Ritzmann, L. W., Sutherland, D. W., & Starr, A. (1966). Urinary Iron Excretion in Patients with Prosthetic Heart Valves. JAMA: The Journal of the American Medical Association, 198(5), 505-510. https://doi.org/10.1001/jama.1966.03110180049017